Challenges in drug and biomarker co-development

Recent Results in Cancer Research

Volumn 195, Issue , 2012, Pages 229-239

  Taube, Sheila E ^a   Lively, Tracy ^b  

^a ST Consulting   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB;

ACCURACY; ARTICLE; BIOASSAY; BREAST CANCER; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CLINICAL EFFECTIVENESS; DISEASE MARKER; DRUG RESEARCH; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860574690     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-28160-0_21     Document Type: Article

References (32)

1. U.S. Department of Health and Human Services (2007) Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. http://www. fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm0715 90.pdf. Accessed 10 July 2011
2. Chakravarty A, Sridhara R (2008) Use of progression-free survival as a surrogate marker in oncology trials: some regulatory issues. Stat Methods Med Res 17:515
3. The European Medicines Agency (2005) http://www.ema.europa.eu/docs/en-GB/ document- library/Regulatory-and-procedural-guideline/2009/10/WC500004883.pdf. Accessed 10 July 2011
4. The European Medicines Agency (2011) http://www.ema.europa.eu/ema/index. jsp?curl= pages/medicines/human/medicines/000795/human-med-001120.jsp&mid= WC0b01ac05800 1d124&murl=menus/medicines/medicines.jsp&jsenabled=true. Accessed 10 July 2011
5. Taube S, Clark G, Dancey J, McShane L, Sigman C, Gutman S (2009) A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 101:1453
6. Clark G (2008) Prognostic factors versus predictive factors: examples from clinical trials of erlotinib. Mol Oncol 1:406
7. Yamauchi H, Stearns V, Hayes D (2001) When is a tumor marker ready for prime time? a case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19:2334
8. Danila D, Fleisher M, Scher H (2011) Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17:3903
9. Slamon D, Godolphin W, Jones L et al (1989) Studies of the HER-2/neu protooncogenein human breast and ovarian cancer. Science 244:707
10. Pegram M, Pauletti G, Slamon D (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52:65
11. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177
12. Bange J, Zwick E, Ullrich A (2001) Molecular targets for breast cancer therapy and prevention. Nat Med 7:548
13. Ross J, Fletcher J, Linette G et al (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8:307
14. Wolff A, Hammond M, Schwartz J et al (2007) American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118
15. Chung K, Shia J, Kemeny N et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803
16. Parra H, Cavina R, Latteri F et al (2004) Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91:208
17. Perez-Soler R, Chachoua A, Hammond L et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238
18. Eberhard D, Johnson B, Amler L, Goddard A, Heldens S, Herbst R, Ince W, Jänne P, Januario T, Johnson D, Klein P, Miller V, Ostland M, Ramies D, Sebisanovic D, Stinson J, Zhang Y, Seshagiri S, Hillan K (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900
19. Jubb A, Harris A (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172
20. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Office of Communications, Division of Information Services (2011) http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 14 July 2011
21. U.S. Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health (2009) http://www.fda.gov/MedicalDevices/Device RegulationandGuidance/ GuidanceDocuments/ucm094533.htm. Accessed 14 July 2011
22. Jiang W, Freidlin B, Simon R (2007) Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 99:1036
23. U.S. Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health (2009) http://www.fda.gov/MedicalDevices/ DeviceRegulationandGuidance/Overview/default. htm#ide. Accessed 14 July 2011
24. Rhodes A, Jasani B, Barnes D, Bobrow L, Miller K (2000) Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: iterlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 53:125
25. Rhodes A, Jasani B, Anderson E, Dodson A, Balaton A (2002) Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 118:408
26. Hammond E, Hayes F, Dowsett M, Allred C, Hagerty K, Badve S, Fitzgibbons P, Francis G, Goldstein N, Hayes M, Hicks D, Lester S, Love R, Mangu P, McShane L, Miller K, Osborne K, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz J, Sweep F, Taube S, Torlakovic E, Valenstein P, Viale G, Visscher D, Wheeler T, Williams B, Wittliff J, Wolff A (2010) American Society of Clinical Oncology-College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784
27. Wolff A, Hammond E, Schwartz J, Hagerty K, Allred C, Cote R, Dowsett M, Fitzgibbons P, Gutman S, Hanna W, Keegan P, Langer A, McShane L, Paik S, Pegram M, Perez E, Press M, Rhodes A, Sturgeon C, Taube S, Tubbs R, Vance G, van de Vijver M, Wheeler T, Yost J, Hayes D (2007) American Society of Clinical Oncology-College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118
28. Allard J, Matera J, Miller C, Repollet M, Connelly M, Rao C, Tibbe A, Uhr J, Terstappen L (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897
29. U.S. Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health (2011) http://www.fda.gov/MedicalDevices/Device RegulationandGuidance/ GuidanceDocuments/ucm262292.htm. Accessed 14 July 2011
30. U.S. Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health (2009) http://www.fda.gov/MedicalDevices/Device RegulationandGuidance/Overview/default. htm#pma. Accessed 14 July 2011
31. U.S. Department of Health and Human Services Centers for Disease Control and Prevention (2004) http://wwwn.cdc.gov/clia/testcat.aspx. Accessed 14 July 2011
32. U.S. Department of Health and Human Services Centers for Disease Control and Prevention (2004) http://wwwn.cdc.gov/clia/regs/toc.aspx. Accessed 14 July 2011